Papaloisou and the EFPIA Disclosure Code 2023

This page makes public Papaloisou’s payments and transfers of value to healthcare professionals/organisations (HCPs/HCOs) and Patient Organisations (POs) based in CYPRUS and GREECE between 01/01/2023 – 31/12/2023.

Papaloisou strongly believes that interactions with HCPs/HCOs/POs positively influence the quality of patient treatment and the value of medical research.

To provide patients with optimal treatment options, HCPs need to stay informed about the latest developments with current and potential new medicines. The pharmaceutical industry has a duty to provide this information. HCPs in turn provide the industry with insights into how to improve medicines by feeding back on how they work in real world settings.

We also recognize that patients expect transparency around these relationships to feel confident that HCPs are impartial and always recommend the most appropriate treatment options. We believe that the European Federation of Pharmaceutical Industry Associations (EFPIA) Disclosure Code, a Code of Conduct that requires all EFPIA member companies to disclose payments and transfer of value to HCPs HCOs and POs, will provide greater transparency around these already well-regulated relationships.

The payments and transfers of value disclosed here were made for activities such as: speaking services during scientific congresses, medical education meetings, participation in advisory boards as well as for research and educational grants, and donations to POs for organising disease awareness campaigns.

To download our assumptions and interpretations of the Disclosure Code click here.

To download a PDF of data for HCPs/HCOs who have provided us with consent to disclose payments made to them as well as aggregate data for those who have not click here.

To download a PDF of data for POs with payments made to them click here.